BACKGROUND: The 5-year survival rate for stage I non-small-cell lung cancer (NSCLC) of 50% to 70% indicates that our current staging methods do not adequately predict outcome. Empty spiracles homeobox 2 (EMX2) is a homeo-domain-containing transcription factor that regulates a key developmental pathway known to promote lung tumorigenesis. This study assessed the significance of EMX2 as a prognostic biomarker in lung adenocarcinoma including bronchioloalveolar carcinoma (BAC). PATIENTS AND METHODS: 144 patients with lung adenocarcinoma undergoing surgical resection were studied. Quantitative real-time reverse transcriptase polymerase chain reaction and Immunohistochemistry were used to analyze EMX2 mRNA and protein expression, respectively. Association of EMX2 mRNA expression levels with clinical outcomes was evaluated using the Kaplan-Meier method and a multivariate Cox proportional hazards regression model. RESULTS: EMX2 mRNA expression was significantly downregulated in lung adenocarcinoma compared with matched adjacent normal tissue (P < .001). EMX2 protein expression was similarly found to be downregulated in lung adenocarcinoma. The EMX2-high mRNA expressing group had statistically significant better overall survival (OS) than the EMX2-low mRNA expressing group (P = .005). Subgroup analysis also demonstrated improved survival in stage I patients (P = .01) and patients with BAC (P = .03). Lastly, the EMX2-high mRNA expressing group had statistically significant better recurrence-free survival (RFS) than the EMX2-low mRNA expression group in patients with adenocarcinoma (P < .001). CONCLUSION: EMX2 expression is downregulated in lung adenocarcinoma. Low EMX2 mRNA expression is significantly associated with decreased OS and RFS in patients with lung adenocarcinoma, particularly with stage I disease and BAC.
BACKGROUND: The 5-year survival rate for stage I non-small-cell lung cancer (NSCLC) of 50% to 70% indicates that our current staging methods do not adequately predict outcome. Empty spiracles homeobox 2 (EMX2) is a homeo-domain-containing transcription factor that regulates a key developmental pathway known to promote lung tumorigenesis. This study assessed the significance of EMX2 as a prognostic biomarker in lung adenocarcinoma including bronchioloalveolar carcinoma (BAC). PATIENTS AND METHODS: 144 patients with lung adenocarcinoma undergoing surgical resection were studied. Quantitative real-time reverse transcriptase polymerase chain reaction and Immunohistochemistry were used to analyze EMX2 mRNA and protein expression, respectively. Association of EMX2 mRNA expression levels with clinical outcomes was evaluated using the Kaplan-Meier method and a multivariate Cox proportional hazards regression model. RESULTS:EMX2 mRNA expression was significantly downregulated in lung adenocarcinoma compared with matched adjacent normal tissue (P < .001). EMX2 protein expression was similarly found to be downregulated in lung adenocarcinoma. The EMX2-high mRNA expressing group had statistically significant better overall survival (OS) than the EMX2-low mRNA expressing group (P = .005). Subgroup analysis also demonstrated improved survival in stage I patients (P = .01) and patients with BAC (P = .03). Lastly, the EMX2-high mRNA expressing group had statistically significant better recurrence-free survival (RFS) than the EMX2-low mRNA expression group in patients with adenocarcinoma (P < .001). CONCLUSION:EMX2 expression is downregulated in lung adenocarcinoma. Low EMX2 mRNA expression is significantly associated with decreased OS and RFS in patients with lung adenocarcinoma, particularly with stage I disease and BAC.
Authors: Keith L Ligon; Yann Echelard; Stavroula Assimacopoulos; Paul S Danielian; Sovann Kaing; Elizabeth A Grove; Andrew P McMahon; David H Rowitch Journal: Development Date: 2003-05 Impact factor: 6.868
Authors: J Okamoto; T Hirata; Z Chen; H-M Zhou; I Mikami; H Li; A Yagui-Beltran; A Beltran; M Johansson; L M Coussens; G Clement; Y Shi; F Zhang; K Koizumi; K Shimizu; D Jablons; B He Journal: Oncogene Date: 2010-08-09 Impact factor: 9.867
Authors: Inderpal S Sarkaria; DuyKhanh Pham; Ronald A Ghossein; Simon G Talbot; Michael Hezel; Maria E Dudas; Michael I Ebright; Shaokun Chuai; Natalie Memoli; Ennapadam S Venkatraman; Vincent A Miller; Mark G Kris; Maureen F Zakowski; Valerie W Rusch; Bhuvanesh Singh Journal: Ann Thorac Surg Date: 2004-11 Impact factor: 4.330
Authors: David G Beer; Sharon L R Kardia; Chiang-Ching Huang; Thomas J Giordano; Albert M Levin; David E Misek; Lin Lin; Guoan Chen; Tarek G Gharib; Dafydd G Thomas; Michelle L Lizyness; Rork Kuick; Satoru Hayasaka; Jeremy M G Taylor; Mark D Iannettoni; Mark B Orringer; Samir Hanash Journal: Nat Med Date: 2002-07-15 Impact factor: 53.440
Authors: Zhilin Liu; Yi A Ren; Stephanie A Pangas; Jaye Adams; Wei Zhou; Diego H Castrillon; Dagmar Wilhelm; JoAnne S Richards Journal: Mol Endocrinol Date: 2015-06-10
Authors: Manuel Pedro Jimenez-García; Antonio Lucena-Cacace; Daniel Otero-Albiol; Amancio Carnero Journal: Cell Death Dis Date: 2021-05-20 Impact factor: 8.469
Authors: Berk Aykut; Markus Ochs; Praveen Radhakrishnan; Adrian Brill; Hermine Höcker; Sandra Schwarz; Daniel Weissinger; Roland Kehm; Yakup Kulu; Alexis Ulrich; Martin Schneider Journal: BMC Cancer Date: 2017-08-22 Impact factor: 4.430
Authors: G Bosco-Clément; F Zhang; Z Chen; H-M Zhou; H Li; I Mikami; T Hirata; A Yagui-Beltran; N Lui; H T Do; T Cheng; H-H Tseng; H Choi; L-T Fang; I-J Kim; D Yue; C Wang; Q Zheng; N Fujii; M Mann; D M Jablons; B He Journal: Oncogene Date: 2013-05-20 Impact factor: 9.867